NHL, Relapsed clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 3-75
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
San Francisco, California and other locations